• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微小RNA在结直肠癌中的结构与临床作用

The Structure and Clinical Roles of MicroRNA in Colorectal Cancer.

作者信息

Zhu Linwensi, Fang Jingyuan

机构信息

Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health and State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institution of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China.

出版信息

Gastroenterol Res Pract. 2016;2016:1360348. doi: 10.1155/2016/1360348. Epub 2016 Dec 28.

DOI:10.1155/2016/1360348
PMID:28115926
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5225333/
Abstract

Colorectal cancer (CRC) is one of the most prevalent types of malignancies, particularly among individuals aged between 50 and 75. The global incidence of CRC has been steadily on the rise due in no small part to an aging population and a shift in lifestyle as well as eating habits. MicroRNAs are a group of small, noncoding, and endogenous RNA molecules that have recently emerged as key players in a broad range of pathological pathways. Moreover, dysregulation of microRNAs has been implicated in cancer development and metastasis. This review is intended to provide a brief overview of the structure, functions, and clinical roles of microRNAs. In particular, the review will focus on the discovery, the underlying mechanistic roles, and the diagnostic as well as therapeutic potentials of CRC-specific miRNAs.

摘要

结直肠癌(CRC)是最常见的恶性肿瘤类型之一,在50至75岁的人群中尤为常见。由于人口老龄化、生活方式和饮食习惯的改变,全球结直肠癌的发病率一直在稳步上升。微小RNA是一组小的、非编码的内源性RNA分子,最近已成为广泛病理途径中的关键参与者。此外,微小RNA的失调与癌症的发生和转移有关。本综述旨在简要概述微小RNA的结构、功能和临床作用。特别是,本综述将重点关注结直肠癌特异性微小RNA的发现、潜在的机制作用以及诊断和治疗潜力。

相似文献

1
The Structure and Clinical Roles of MicroRNA in Colorectal Cancer.微小RNA在结直肠癌中的结构与临床作用
Gastroenterol Res Pract. 2016;2016:1360348. doi: 10.1155/2016/1360348. Epub 2016 Dec 28.
2
Recent advances in the diagnostic and therapeutic roles of microRNAs in colorectal cancer progression and metastasis.微小RNA在结直肠癌进展和转移中的诊断及治疗作用的最新进展
Front Oncol. 2022 Oct 13;12:911856. doi: 10.3389/fonc.2022.911856. eCollection 2022.
3
Interactions among lncRNAs, miRNAs and mRNA in colorectal cancer.长链非编码 RNA、微小 RNA 和信使 RNA 在结直肠癌中的相互作用。
Biochimie. 2019 Aug;163:58-72. doi: 10.1016/j.biochi.2019.05.010. Epub 2019 May 10.
4
The Dual Role of MicroRNAs in Colorectal Cancer Progression.microRNAs 在结直肠癌进展中的双重作用
Int J Mol Sci. 2018 Sep 17;19(9):2791. doi: 10.3390/ijms19092791.
5
MicroRNA: A new player in response to therapy for colorectal cancer.微小 RNA:结直肠癌治疗反应的新角色。
J Cell Physiol. 2019 Jun;234(6):8533-8540. doi: 10.1002/jcp.27806. Epub 2018 Nov 27.
6
Involvement of Non-coding RNAs in the Signaling Pathways of Colorectal Cancer.非编码RNA在结直肠癌信号通路中的作用
Adv Exp Med Biol. 2016;937:19-51. doi: 10.1007/978-3-319-42059-2_2.
7
MicroRNAs as novel biomarkers for colorectal cancer: New outlooks.微小 RNA 作为结直肠癌的新型生物标志物:新展望。
Biomed Pharmacother. 2018 Jan;97:1319-1330. doi: 10.1016/j.biopha.2017.11.046. Epub 2017 Nov 14.
8
MicroRNA-130a is upregulated in colorectal cancer and promotes cell growth and motility by directly targeting forkhead box F2.微小 RNA-130a 在结直肠癌中上调,并通过直接靶向叉头框 F2 促进细胞生长和迁移。
Mol Med Rep. 2017 Oct;16(4):5241-5248. doi: 10.3892/mmr.2017.7257. Epub 2017 Aug 16.
9
MicroRNAs as potential drug targets for therapeutic intervention in colorectal cancer.微小RNA作为结直肠癌治疗干预的潜在药物靶点。
Expert Opin Ther Targets. 2015;19(12):1705-23. doi: 10.1517/14728222.2015.1069816. Epub 2015 Jul 18.
10
One step ahead: miRNA-34 in colon cancer-future diagnostic and therapeutic tool?领先一步:结肠癌中的 microRNA-34——未来的诊断和治疗工具?
Crit Rev Oncol Hematol. 2018 Dec;132:1-8. doi: 10.1016/j.critrevonc.2018.09.006. Epub 2018 Sep 15.

引用本文的文献

1
CircRNA-SCAF8 promotes vascular endothelial cell pyroptosis by regulating the miR-93-5p/TXNIP axis.环状 RNA-SCAF8 通过调控 miR-93-5p/TXNIP 轴促进血管内皮细胞焦亡。
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023 Aug 25;52(4):473-484. doi: 10.3724/zdxbyxb-2023-0091.
2
miR-361-5p regulates ovarian cancer cell proliferation and apoptosis by targeting TRAF3.微小RNA-361-5p通过靶向肿瘤坏死因子受体相关因子3调控卵巢癌细胞的增殖和凋亡。
Exp Ther Med. 2021 Mar;21(3):199. doi: 10.3892/etm.2021.9632. Epub 2021 Jan 11.
3
Integrated analyses of microRNA-29 family and the related combination biomarkers demonstrate their widespread influence on risk, recurrence, metastasis and survival outcome in colorectal cancer.对微小RNA-29家族及相关联合生物标志物的综合分析表明,它们对结直肠癌的风险、复发、转移及生存结局具有广泛影响。
Cancer Cell Int. 2019 Jul 15;19:181. doi: 10.1186/s12935-019-0907-x. eCollection 2019.
4
MicroRNA-16 inhibits migration and invasion via regulation of the Wnt/β-catenin signaling pathway in ovarian cancer.微小RNA-16通过调控Wnt/β-连环蛋白信号通路抑制卵巢癌的迁移和侵袭。
Oncol Lett. 2019 Mar;17(3):2631-2638. doi: 10.3892/ol.2019.9923. Epub 2019 Jan 14.
5
Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies.当前关于 miRNA 作为检测结直肠癌化疗耐药性的潜在治疗和诊断标志物的证据:临床前和临床研究的系统评价和荟萃分析。
Mol Diagn Ther. 2019 Feb;23(1):65-82. doi: 10.1007/s40291-019-00381-6.
6
The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas.miR-192/215 微家族在黏液性卵巢癌中上调。
Sci Rep. 2018 Jul 23;8(1):11069. doi: 10.1038/s41598-018-29332-7.
7
MicroRNAs as Biomarkers in Colorectal Cancer.微小RNA作为结直肠癌的生物标志物
Cancers (Basel). 2017 Sep 13;9(9):124. doi: 10.3390/cancers9090124.
8
MiR-29b inhibits the growth of glioma via MYCN dependent way.微小RNA-29b通过依赖MYCN的方式抑制神经胶质瘤的生长。
Oncotarget. 2017 Jul 11;8(28):45224-45233. doi: 10.18632/oncotarget.16780.

本文引用的文献

1
miR-152 functions as a tumor suppressor in colorectal cancer by targeting PIK3R3.miR-152通过靶向PIK3R3在结直肠癌中发挥肿瘤抑制作用。
Tumour Biol. 2016 Aug;37(8):10075-84. doi: 10.1007/s13277-016-4888-2. Epub 2016 Jan 28.
2
MiR-382 inhibits cell growth and invasion by targeting NR2F2 in colorectal cancer.微小RNA-382通过靶向核受体亚家族2F组成员2抑制结直肠癌细胞的生长和侵袭。
Mol Carcinog. 2016 Dec;55(12):2260-2267. doi: 10.1002/mc.22466. Epub 2016 Jan 22.
3
Fecal miR-29a and miR-224 as the noninvasive biomarkers for colorectal cancer.粪便中的miR-29a和miR-224作为结直肠癌的非侵入性生物标志物。
Cancer Biomark. 2016;16(2):259-64. doi: 10.3233/CBM-150563.
4
Transcatheter arterial infusion chemotherapy increases expression level of miR-142-5p in stage III colorectal cancer.经导管动脉灌注化疗可提高III期结直肠癌中miR-142-5p的表达水平。
Indian J Cancer. 2015 Dec;52 Suppl 2:e47-55. doi: 10.4103/0019-509X.172513.
5
The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.血浆微小RNA miR-1914*和-1915通过下调NFIX抑制结直肠癌患者的化疗耐药性。
Curr Mol Med. 2016;16(1):70-82. doi: 10.2174/1566524016666151222144656.
6
Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma.微小RNA-24、微小RNA-320a和微小RNA-423-5p的血浆水平是结直肠癌的潜在生物标志物。
J Exp Clin Cancer Res. 2015 Aug 22;34(1):86. doi: 10.1186/s13046-015-0198-6.
7
Stromal expression of miR-21 in T3-4a colorectal cancer is an independent predictor of early tumor relapse.miR-21在T3-4a期结直肠癌中的基质表达是早期肿瘤复发的独立预测指标。
BMC Gastroenterol. 2015 Jan 22;15:2. doi: 10.1186/s12876-015-0227-0.
8
microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma.粪便中microRNA-221和microRNA-18a的鉴定作为结直肠癌非侵入性诊断的潜在生物标志物
Br J Cancer. 2014 Oct 28;111(9):1765-71. doi: 10.1038/bjc.2014.484. Epub 2014 Sep 18.
9
Meta-analysis of the differentially expressed colorectal cancer-related microRNA expression profiles.结直肠癌相关微小RNA差异表达谱的Meta分析
Eur Rev Med Pharmacol Sci. 2014;18(14):2048-57.
10
MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression.微小RNA-17-5p通过抑制PTEN表达促进结直肠癌的化疗耐药性和肿瘤转移。
Oncotarget. 2014 May 30;5(10):2974-87. doi: 10.18632/oncotarget.1614.